secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001104659-22-125884
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Pharma receives Nasdaq deficiency for MVPHS < $15M; faces delisting by Jan 2, 2023
--------------------------------------------------------------------------------

- On Dec 5, 2022, Nasdaq notified Kala that market value of publicly held shares was below $15M for 30 consecutive business days.
- Company has 180 days (until June 5, 2023) to regain compliance; needs MVPHS >= $15M for 10 consecutive days.
- Prior July 2022 deficiency for failing multiple Global Select Market standards; must cure by Jan 2, 2023 or face delisting.
- Kala may transfer to Nasdaq Capital Market if compliance not regained; remains out of compliance with Rule 5450(b).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465922125884/0001104659-22-125884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465922125884/tm2232346d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-125884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer